Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Germ cell tumors: dose-intensive therapy

W Siegert1, J Beyer

  • 1Abt. für Innere Medizin und Poliklinik m.S. Hämatologie und Onkologie Virchow Klinikum, Humboldt Universität, Berlin, Germany.

Seminars in Oncology
|April 30, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I.

Clinical science (London, England : 1979)·2000
Same author

Reconstruction and visualization of irregularly sampled three- and four-dimensional ultrasound data for cerebrovascular applications.

Ultrasound in medicine & biology·2000
Same author

[Comparison of hypoglycemia perception and hormonal counterregulation in controlled hypoglycemia. A contribution to diagnosis of hypoglycemia unawareness syndrome in type 1 diabetic patients].

Deutsche medizinische Wochenschrift (1946)·2000
Same author

[Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].

Deutsche medizinische Wochenschrift (1946)·2000
Same author

[Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation].

Deutsche medizinische Wochenschrift (1946)·2000
Same author

Pseudorabies virus expressing bovine herpesvirus 1 glycoprotein B exhibits altered neurotropism and increased neurovirulence.

Journal of virology·2000

High-dose chemotherapy using carboplatin and etoposide offers a safe and effective treatment for germ cell tumors, even in relapsed or advanced cases. This intensive approach shows promise for overcoming cisplatin resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Germ cell tumors (GCTs) can be challenging to treat, especially in relapsed or advanced stages.
  • Conventional chemotherapy may not be sufficient for all GCT patients.
  • Advances in supportive care, including growth factors and autologous stem cell transplantation, have improved the safety of intensive chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of dose-intensive chemotherapy with carboplatin and etoposide in germ cell tumor patients.
  • To explore the potential of high-dose chemotherapy to overcome cisplatin resistance.
  • To assess the feasibility of initiating high-dose treatment earlier in the disease course.

Main Methods:

  • Administration of carboplatin (1000-2000 mg/m2) and etoposide (1200-2400 mg/m2) in one or two cycles.

Related Experiment Videos

  • Use of growth factors and autologous stem cells for hematopoietic rescue.
  • Treatment applied to patients with multiply relapsed or advanced GCTs, and considered for first-line salvage or poor-risk patients.

    • Main Results:

    • Achieved long-term disease-free survival in a subset of patients with previously incurable disease.
    • Demonstrated that high-dose carboplatin and etoposide can overcome cisplatin refractoriness.
    • High-dose treatment (HDT) is better tolerated when instituted earlier in the disease course.

    Conclusions:

    • Dose-intensive chemotherapy with carboplatin and etoposide is a viable and relatively safe option for GCT patients, including those with refractory disease.
    • Early application of HDT may lead to superior tumor eradication and improved outcomes.
    • Further randomized studies are needed to confirm the definitive value of HDT in GCT treatment.